Rhythm Pharmaceuticals, Inc. (RYTM) Cash Flow Statement

The ratio of operating cash flow to net income is not a conventional cash generation signal here because both figures are negative, so the relevant reading is how much of the reported loss is cash-consuming. The company's cash outflow in Q2 and Q1 2026 exceeded its net loss, which suggests working capital drag and timing effects were adding to operating burn in those periods rather than masking it. Investors should monitor whether the non-cash add-backs continue to represent a large share of expenses, as that dynamic affects how much of the loss requires external funding.

The sharp narrowing in the latest quarter is driven by a working capital inflow of $9.6M and reduced cash burn, which reads as partly timing-dependent rather than a proven structural shift. Revenue growth has not yet translated into sustained free cash flow generation, indicating that the commercial cost base still absorbs the gross profit. The trajectory warrants monitoring over additional quarters before concluding that the business is approaching self-funding.

The absence of distributions is consistent with a company in a cash-consumption phase, where every dollar of available liquidity supports commercial launch and development costs. Given the reported cash balance of $54.3M against a trailing net loss exceeding $190M, the capital position appears to leave limited room for discretionary deployment. Investors should watch for any future equity or debt issuance, which would be the more likely form of capital inflow than internally generated returns to shareholders.